(TB_PREV) Proportion of ART patients who completed a standard course of TB preventive therapy within the reporting period
Export Indicator
This indicator measures the performance of HIV programs in scaling up TB preventive therapy, with the goal of preventing progression to active TB disease among PLHIV and decreasing ongoing TB transmission in this population. The denominator will inform programs on the pace of scale-up, and the proportion will inform programs on how well preventive therapy itself is being administered. New timing and sex disaggregates will inform programs on how well they are linking those who screen negative for TB to TB preventive therapy, and allow for monitoring of cohorts from initiation to completion of therapy.
The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period
The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfilled the minimum requirements for the previous reporting period).
Sum Numerator / sum denominator
The denominator can be generated by counting the total number of patients who were started on TB preventive therapy in the reporting period, or who started the reporting period already on TB preventive therapy (as long as they had taken less than 6 months of therapy). The numerator can be generated by counting the number of PLHIV who are documented as having received at least six months of isoniazid preventive therapy, or completed a standard course of TB preventive therapy. This should include the patients who completed a shorter alternative course, such as three months of isoniazid and rifapentine, as well as those who are on continuous IPT who have taken at least six months. These data should be captured in IPT and/or ART registers as well as additional data collection sources (i.e., patient treatment cards, medical charts, pharmacy records). Programs should modify the registers as needed to easily capture this information.
How to review for data quality
Only one disaggregation type is used for age (coarse disaggregations). Data Element ≥ subtotal of each of the disaggregations.
Reporting Level
Site level: facility and community
Semi-Annual
Numerator: ART patients who have ever completed a standard course or at least 6 months of IPT during the reporting period.
Type of therapy
1. 6-12 months IPT
2. Continuous IPT
3. Alternative regimen (e.g., 3 month INH and rifapentine)
Age/Sex (Coarse Disaggregate)
<15 F, 15+ F, <15 M, 15+ M
Denominator: ART patients who were newly started on TB preventive therapy, or who were continuing TB preventive therapy from the previous reporting period
Type of therapy by Start of therapy
1. 6-12 months IPT by
- a. Started during this reporting period
- b. Started in last reporting period
2. Continuous IPT
- a. Started during this reporting period
- b. Started in last reporting period 1.
2. Alternative regimen (e.g., 3 months of INH and rifapentine)
a. Started during this reporting period
b. Started in last reporting period
Age/Sex (Coarse Disaggregate)
<15 F, 15+ F, <15 M, 15+ M
MER 1.0 to 2.0 Change
This is a new indicator, replacing TB_IPT
- Indicator title revised to indicate change to completed therapy, and change from ”isoniazid only” to include other TB preventive regimens (e.g., Rifampicin or INH/Rifapentine)
- Type of therapy disaagregation to indicate whether ART patients started time-limited IPT, continuous IPT or an alternative regimen
- Timing disaggregation added to whether the ART patients initiated TB preventive therapy during the current reporting period or previously
- The fine age/sex disaggregations have been dropped in order to align with the TX_TB indicator to which this indicator closely relates.
PEPFAR Support definition
Standard definition of DSD and TA-SDI used.
Provision of key staff or commodities for routine HIV-related services include: ongoing provision of critical re-occurring costs or commodities (such as ARVs, TB preventive therapy and diagnostic/screening tests) or funding of salaries or provision of Health Care Workers for HIV clinic services. Staff responsible for maintaining patient records in both HIV and TB clinics are included in this category however staff responsible for fulfilling reporting and routine M&E requirements are not included.
Ongoing support for patients receiving routine HIV-related services includes: training of HIV service providers, clinical mentoring and supportive supervision of staff at HIV sites, infrastructure/renovation of facilities, support of HIV service data collection, reporting, data quality, QI/QA of HIV services support, ARV and IPT consumption forecasting and supply management, support of lab clinical